Abstract text (incl. figure legends and references)

Objective: To assess the real-world effectiveness and healthcare resource utilization (HCRU) of fremanezumab in adults with episodic/chronic migraine (EM/CM) treated by multiple physicians from the UK.

Methods: This UK panel-based online physician chart review used electronic case report forms. Patient inclusion criteria included a physician diagnosis of CM/EM in Scotland and CM in England, Wales, and Northern Ireland; first fremanezumab treatment initiation (index date) at aged ≥18 years from June 2020–October 2021; ≥3 months of continuous treatment after index date; monthly migraine days (MMD) and monthly headache days (MHD) assessments 1 month before (pre-index) and 3 months (±15 days) after (post-index) initiation; and ≥3 months of information about migraine treatments prior to index date. Migraine-related HCRU was compared for 6 months pre- and post-index. P

Results: Data were included from 42 neurologists and 183 patients (mean age[SD], 40.5[11.3]; female, 129[70.5%]; CM diagnosis, 174[95.1%]). 95(51.9%) patients initiated monthly fremanezumab dosing, and 88(48.1%) initiated quarterly dosing. Reductions in MMD were observed across dosing subgroups after 3 months of treatment (percent reduction from baseline: overall, 51.9[25.7]; monthly, 52.9[28.3]; quarterly, 50.8[22.7]; all P<0.001). Reductions in MHD were also observed (percent reduction from baseline: overall, 47.3[27.0]; monthly, 49.2[28.3]; quarterly, 45.0[25.5]; all P≤0.002). Reductions in HCRU were observed from 6 months pre-index to 6 months post-index: outpatient office visits (P=0.005); urgent care/ER visits (P=0.001); inpatient admissions (P=0.028). Reductions, not statistically significant, were observed in the number of telehealth consultations.

Conclusions: Fremanezumab reduced MMD and MHD after 3 months and reduced migraine-related HCRU after 6 months in a real-world UK population of patients with migraine from multiple physicians.